From the Director:

Richard V. Decker, MD
Director, USC Norris Comprehensive Cancer Center
Norris, a University of Southern California Medical Center

Caryn Lerman, PhD
Associate Dean for Cancer Programs

Community for a Cure

Have something to contribute to Community for a Cure? Send it to jculver@med.usc.edu

Dr. Mohamed Abou-el-Enein, MD, PhD, MSPH
Professor of Medicine
USC Norris Comprehensive Cancer Center

Associate Dean for Cancer Programs

The 5-year survival rate for metastatic colorectal cancer (CRC) remains grim as the cancer was located towards the center of both her left and right kidneys. Before coming to USC Norris, her physician had told her that the cancer was incurable. She was diagnosed with metastatic renal cell cancer that had spread to her bones, lungs, and liver in 2012. She received several different treatments, providing new data to inform drug development for this disease. This study is expected to identify factors that influence the behavior of tumor cells and how they respond to different treatments.

El Amin Kishk, MD, PhD
Professor of Medicine
USC Norris Comprehensive Cancer Center

Associate Dean for Cancer Programs

Dr. Mohamed Abou-el-Enein, MD, PhD, MSPH
Professor of Medicine
USC Norris Comprehensive Cancer Center

Associate Dean for Cancer Programs

The USC Norris Comprehensive Cancer Center (USC Norris) is an academic cancer center on the campus of the University of Southern California (USC). USC Norris, with an annual budget of $225 million, is one of the largest cancer centers in the nation and one of the top 10 cancer centers in the country, as validated by U.S. News & World Report.

Robert Weiner, MD
Chair, Department of Medicine
Norris, a University of Southern California Medical Center

Dr. Robert Weiner, MD, is an influential leader in the field of investigating how various drugs and other treatments can be used to fight different cancers, as well as cancer stem cell biology.

Dr. Robert Weiner, MD, is an influential leader in the field of investigating how various drugs and other treatments can be used to fight different cancers, as well as cancer stem cell biology. He is also an expert in the treatment of chronic lymphocytic leukemia (CLL), a type of blood cancer that affects cells of the immune system. Dr. Weiner is the senior investigator on the CLL studies that led to the development of ibrutinib, a new drug that has been shown to be effective in treating CLL.

Dr. Robert Weiner, MD, is the director of the CLL Laboratory at USC Norris, where he leads a team of researchers who are investigating new drugs and other treatments for CLL. His lab has published numerous papers on the use of ibrutinib in the treatment of CLL, and he has presented his findings at numerous national and international conferences. Dr. Weiner is also a member of the CLL Society, a non-profit organization that supports research into CLL and provides resources for patients and caregivers.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the CLL Society, a non-profit organization that supports research into CLL and provides resources for patients and caregivers. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.

Dr. Robert Weiner, MD, is a member of the National Cancer Institute (NCI) CLL Working Group, and he has served on the CLL subcommittee of the NCI's Cancer Therapy Evaluation Program. He has also been involved in clinical trials of new drugs for CLL, including ibrutinib.